Table 1

Characteristics of the study sample
Total sample (#349) EA (#65) NEA (#284) p CD(#155) NCD (#194) p
Age at conception (mean, SD, years) 31.8 (4.7) 32.5 (4.7) 31.7 (4.7) 0.232 31.7 (4.7) 31.8 (4.7) 0.907
Age at onset (mean, SD, years) 24.7 (5.8) 24.6 (6.4) 24.8 (5.7) 0.860 24.5 (6.0) 24.8 (5.7) 0.550
Disease duration at conception (mean, SD, years) 7.1 (4.8) 7.8 (5.9) 6.97 (4.5) 0.279 7.27 (4.8) 7.0 (4.8) 0.689
EDSS at conception (mean, SD) 1.5 (1.0) 1.5 (0.97) 1.5 (0.98) 0.868 1.6 (1.0) 1.4 (0.92) 0.107
Treated with DMDs before pregnancy (#, %) 176 (50.4) 28 (43.1%) 147 (51.8) 0.226 87 (56.1) 89 (45.9) 0.057
Relapses in the year prior to pregnancy (mean, SD) 0.4 (0.7) 0.37 (0.6) 0.39 (0.7) 0.800 0.38 (0.73) 0.39 (0.7) 0.937
Relapses during pregnancy (mean, SD) 0.12 (0.4) 0.1 (0.3) 0.11 (0.3) 0.950 0.15 (0.42) 0.09 (0.29) 0.157
Relapses in the year after the delivery (mean, SD) 0.45 (0.7) 0.35 (0.57) 0.48 (0.76) 0.130 0.47 (0.8) 0.44 (0.67) 0.677
Exclusive breastfeeding (#,%) 162 (46.4) 19 (29.2) 99 (34.9) 0.370 47 (30.3) 71 (36.6) 0.316

EA: epidural analgesia.

NEA: Not epidural analgesia.

CD: caesarean delivery.

NCD: not caesarean delivery.

SD: Standard Deviation.

EDSS: Expanded Disability Status Scale.

DMDs: Disease Modifying Drugs.

Pastò et al.

Pastò et al. BMC Neurology 2012 12:165   doi:10.1186/1471-2377-12-165

Open Data